IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDEAYA reported Q2 2026 collaboration revenue of $8.9 million with a net loss of $112.5 million, or $1.22 per share, while strengthening its balance sheet to $1.24 billion in cash following a recent offering. The company announced that its registrational Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib met its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival of 6.9 months versus 3.1 months in the control arm.
Key figures
- Revenue
- 8900000
- P value
- <0.0001
- Net loss
- 112500000
- Rd expenses
- 108700000
- Hazard ratio
- 0.42
- Cash position
- 1240000000
- Pfs control months
- 3.1
- Pfs treatment months
- 6.9
- Net proceeds offering
- 323400000
- Servier revenue balance
- 147000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.